Allergan Aesthetics received FDA approval for SKINVIVE by JUVÉDERM for improvement of neck appearance. The indication targets skin quality and laxity in the neck and décolletage—a high-demand area that many practices treat off-label with existing fillers or biostimulators.
Regulatory
Allergan Gets FDA Nod for SKINVIVE by JUVÉDERM for Neck — New Indication, Same Filler
Hyaluronic acid filler gains regulatory clearance for neck skin quality; expands addressable market for existing patient base.
Formalizes off-label neck use and expands the addressable market for hyaluronic acid fillers.
SKINVIVE is a smooth, injectable hyaluronic acid gel formulated for superficial placement to improve skin texture and hydration. The approval formalizes a use case practices already pursue, but now with on-label claims and reimbursement potential for certain clinical scenarios. This is a volume play for Allergan: it leverages existing manufacturing and distribution, captures incremental syringe sales from established accounts, and gives practices labeled language for patient education. The neck remains an undertreated zone—many patients defer it until later in treatment progression.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.